Bisphosphonates used in the management of osteoporosis are usually well tolerated In two separate systematic reviews of oral bisphosphonate therapy (alendronate and risedronate) there was no statistically significant difference in adverse events in the active versus placebo arm 1 2 The most commonly reported adverse effects from observational post-marketing data of oral bisphosphonate However it is still unclear about how bisphosphonate could grant chondrocytes a new lease of life after traumatic damage The central hypothesis of this study is that the chondro-protective function of ZA is attributable to its direct effect on chondrocytes In specific we will test the following

Skeletal complications of bisphosphonate use: what the

The estimated risk of BRONJ in patients receiving anti-resorptive therapy is rare The occurrence in oral bisphosphonate use is estimated to be between 1 in 10 000 and 1 in 100 000 patient years with more frequent occurrences in females and age groups older than 60 years [13 14] The majority of reported cases of BRONJ (approximately 95%) are associated with iv bisphosphonate therapy in the

clinical studies have found adverse effects of alendronic acid on bone (Burr et al 2) 2 3 Clinical aspects 2 3 1 Introduction Cases of atypical stress fractures in association with bisphosphonates have been described in the literature using a variety of terms such as pathological

Intravenous bisphosphonate therapy is considered more effective than oral therapies at least in preventing recurrent vertebral fractures [Grover: 2017] Most studies of intravenous bisphosphonates for pediatric therapy include pamidronate and zoledronic acid Oral bisphosphonates such as alendronate or risedronate have less evidence for use

Jan 01 2020A topical irritant effect of oral bisphosphonates on the gastric mucosa has also been shown due to reduction in the protective hydrophobic barrier [15 16] This is supported by the finding that most alendronate gastric ulcers are found in the greater curve of the gastric antrum [ 3 ] where tablets would usually settle due to gravity [ 10 ]

Jan 01 2020A topical irritant effect of oral bisphosphonates on the gastric mucosa has also been shown due to reduction in the protective hydrophobic barrier [15 16] This is supported by the finding that most alendronate gastric ulcers are found in the greater curve of the gastric antrum [ 3 ] where tablets would usually settle due to gravity [ 10 ]

Dental side effects of bisphosphonates

Bisphosphonates are also used for treatment of cancer Bamias Kastritis and Bamia are cited finding 6 7 percent of 250 people treated for cancer with bisphosphonates developing jaw osteonecrosis including 10 percent of those treated for myeloma developing this side effect Zoledronic acid was associated with the highest incidence of

Bisphosphonates are pharmacological agents which are currently used both in osteoporosis than in other pathological conditions characterised by an increased bone resorption such as Paget's disease of bone malign hypocalcaemia during myeloma osteolytic bone metastasis and fibrous dysplasia of bone

clinical studies have found adverse effects of alendronic acid on bone (Burr et al 2) 2 3 Clinical aspects 2 3 1 Introduction Cases of atypical stress fractures in association with bisphosphonates have been described in the literature using a variety of terms such as pathological

Side effects of denosumab are similar to bisphosphonates but these drugs are more likely to result in a low calcium level with long-term use For this reason taking a supplement of calcium and vitamin D is often recommended Unlike bisphosphonates denosumab may be used in

Mar 18 2009Bisphosphonates are osteoclast inhibitors and act directly on the bone to inhibit bone resorption 4 A number of studies have evaluated the use of oral and intravenous bisphosphonates in AI-induced bone loss 9-14 In general studies investigating oral agents including risedronate alendronate and ibandronate effectively maintained or improved

Bisphosphonates are also used for treatment of cancer Bamias Kastritis and Bamia are cited finding 6 7 percent of 250 people treated for cancer with bisphosphonates developing jaw osteonecrosis including 10 percent of those treated for myeloma developing this side effect Zoledronic acid was associated with the highest incidence of

Sep 01 2003Bisphosphonates have an established role in treating tumor-inducedhypercalcemia and decreasing the incidence of skeletal-related events Recent data suggest that these agents may also prevent skeletal metastases This review explains how cancer metastasizes to bone and howbisphosphonates may block this process with a summary of clinicaltrials supporting the use of bisphosphonates

Jan 01 2020A topical irritant effect of oral bisphosphonates on the gastric mucosa has also been shown due to reduction in the protective hydrophobic barrier [15 16] This is supported by the finding that most alendronate gastric ulcers are found in the greater curve of the gastric antrum [ 3 ] where tablets would usually settle due to gravity [ 10 ]

Repurposing of bisphosphonates for the prevention and

Small molecules to target oncogenic signaling cascades in cancer have achieved success in molecularly defined patient subsets The path to approval is often protracted and plagued with failures Repositioning Food and Drug Administration-approved drugs with known side effects has become a major focus Bisphosphonates are a commonly prescribed therapy for osteoporosis and skeletal metastases

Title:Irsogladine : Overview of the Mechanisms of Mucosal Protective and Healing- Promoting Actions in the Gastrointestinal Tract VOLUME: 19 ISSUE: 1 Author(s):Michiyo Akagi Kikuko Amagase Toshiko Murakami and Koji Takeuchi Affiliation:Department of Pharmacology and Experimental Therapeutics Division of Pathological Sciences Kyoto Pharmaceutical University Misasagi Yamashina Kyoto 607

CYSHCN may have osteopenia or osteoporosis leading to pathologic fractures While some children are born with primary bone conditions such as osteogenesis imperfecta many CYSHCN are at increased risk for pathological fractures due to decreased mobility decreased calcium and/or vitamin D intake inadequate dietary protein steroid or growth hormone disruptions decreased absorption of

Oct 12 2015Furthermore the bisphosphonates are retained in bone for some time after treatment is stopped and the effects can continue for months or years after treatment has been stopped Add to this the fact that the risk of serious adverse effects increases with length of treatment and it is clear why the concept of a drug holiday has been introduced

Clinical trials are investigating the use of bisphosphonates in patients with early (nonmetastatic) breast cancer Results from trials of clodronate are generally encouraging but somewhat contradictory Of the three trials published to date two reported that clodronate had beneficial effects on both bone metastases and survival